^
Association details:
| Biomarker: | EGFR mutation + FAT3 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPLAR and OAK Trials
Published date:
08/08/2023
Excerpt:
56 EGFR-mutated patients treated with atezolizumab were ultimately enrolled….Similarly, patients with EGFR&FAT3 CoMut showed increased ORR than EGFR SM counterparts (33.33% vs 6.25%, P = 0.0894) (Fig. 1E) and significantly prolonged PFS (9.27 months vs 2.53 months; P = 0.0247) (Fig. 1F).
